Original Article: bit.ly/1AdjmjB
The results of two European studies have confirmed that PrEP (pre-exposure prophylaxis) can reduce the rate of HIV infection in men who have sex with men (MSM).
However, not all studies are created equally — one matched the Center for Disease Control and Prevention (CDC) recommended dosing strategy of one pill, taken daily, while the other study tried a more novel approach, with participants taking the pill as needed, depending on when they had sex.
First, the British study. Conducted by the U.K. Medical Research Group in an open-label study called PROUD, MSM were split into two groups, with one given a daily dose of Truvada, brand name for tenofovir plus emtricitabine. The findings of the study confirmed those of multiple other studies around the world, that a daily regimen of PrEP can reduce the rate of HIV infection — in this case, by 86% among study participants.
Full text of article available at link below: bit.ly/1AdjmjB